Aflatoxin and Ochratoxin A in Botanical Supplements: The Mycotoxin Risk Most Brands Don't Screen For

Aflatoxin B1 is classified by the International Agency for Research on Cancer as a Group 1 human carcinogen — in the same tier as asbestos and tobacco smoke. It grows invisibly on ginger root, turmeric, licorice, ashwagandha, and dozens of other botanical ingredients that end up in dietary supplements sold across the United States. And a significant share of the brands selling those products have never run a single mycotoxin test on their raw materials.

That’s not a theoretical gap. FDA has issued import alerts and warning letters specifically over mycotoxin contamination in botanical ingredients for years. California’s Prop 65 lists aflatoxin B1 as a carcinogen with no established safe harbor level — which means any detectable exposure in a product sold into California is potential litigation exposure. And supplier COAs, in most cases, say nothing about mycotoxins at all.

Mycotoxins are easy to overlook because they’re invisible, odorless, and stable through heat, extraction, and encapsulation. Processing doesn’t neutralize them. Neither does reformulation. The only control point is raw material acceptance — which means you need a testing protocol before the material enters your facility, not after.

Why Botanical Ingredients Carry Disproportionate Mycotoxin Risk

Not all supplement ingredients share the same contamination profile. Whey protein and fish oil have their challenges. But botanical raw materials occupy a distinct risk category for three compounding reasons.

First, most botanicals are grown, dried, and initially stored in tropical and subtropical regions — India, China, West Africa, Central America — where humidity and temperature conditions favor mold growth. Aflatoxins (B1, B2, G1, and G2) are produced primarily by Aspergillus flavus and A. parasiticus. Ochratoxin A (OTA) comes mainly from Aspergillus ochraceus and certain Penicillium species. Both thrive when raw material moisture content exceeds approximately 14–16% and temperatures stay above 25°C — conditions that are common during post-harvest handling and ocean freight, even when growers start with clean lots.

Second, supply chains are long. By the time a botanical extract reaches a US contract manufacturer, it has typically passed through three to five intermediaries. Each transfer is an opportunity for improper storage. Mold proliferation can occur after initial quality checks have already cleared a lot.

Third, concentration amplifies the problem in a way many brands don’t account for. You’re not encapsulating raw turmeric root — you’re often using a 10:1 or 20:1 standardized extract. If the starting material contains aflatoxin at 5 µg/kg, a 20:1 extract derived from it could carry contamination at or near 100 µg/kg. That math matters enormously when FDA’s action level is 20 µg/kg total aflatoxins and USP <561> limits aflatoxin B1 to just 2 µg/kg.

High-risk botanicals include ginger, turmeric, black pepper, licorice root, psyllium husk, ashwagandha, milk thistle, ginkgo biloba, saw palmetto, and most dried spice-derived ingredients. These appear repeatedly in contamination surveillance programs. If your formulation contains any of them, routine mycotoxin screening is not a quality enhancement — it’s the baseline expectation of a defensible quality program.

What the Limits Actually Require — FDA, USP <561>, and California Prop 65

Multiple regulatory frameworks apply simultaneously here, and they don’t align neatly. Brand owners who rely on only one of them are usually relying on the wrong one.

FDA action levels. FDA’s action level for total aflatoxins in food and feed is 20 µg/kg (parts per billion). There is no separate FDA mycotoxin limit specifically for dietary supplements — the agency applies food standards. FDA has enforced against aflatoxin contamination in botanical supplement ingredients through import alerts and 483 observations when levels approach or exceed this threshold.

USP <561>. The United States Pharmacopeia’s chapter on Articles of Botanical Origin sets limits specifically for botanical materials. USP <561> requires no more than 2 µg/kg aflatoxin B1 and no more than 4 µg/kg total aflatoxins (B1, B2, G1, and G2 combined) in botanical articles. That is five to ten times stricter than FDA’s food action level. For any supplement program referencing USP standards — and most GMP-compliant programs do — USP <561> is effectively the operative limit, not the FDA food threshold.

Ochratoxin A. There is no federal US limit for OTA in dietary supplements or botanical ingredients. EU Regulation EC 1881/2006 sets OTA maximums in food, ranging from 3 µg/kg in cereals to 30 µg/kg in spices. Many US supplement brands default to EU benchmarks for OTA because there’s nothing domestic to reference. That’s a reasonable approach — especially for brands that export or are building toward European market access.

California Prop 65. Aflatoxin B1 is a listed Prop 65 carcinogen. Crucially, no No Significant Risk Level (NSRL) has been established for aflatoxin B1 — meaning there is no concentration below which you’re automatically safe from warning requirements. Prop 65 is primarily enforced by private plaintiff attorneys, not state agencies, which makes it a live litigation risk for any supplement brand with California distribution. The standard of evidence required to trigger a notice of violation is low.

Put together: a brand selling botanical supplements in California should be testing to USP <561> limits at minimum, using EU benchmarks for OTA, and targeting aflatoxin B1 results as close to non-detectable as the analytical method can achieve.

Choosing a Testing Method — When ELISA Is Enough and When You Need LC-MS/MS

There are three main analytical approaches to mycotoxin testing, and they serve different purposes.

Immunoassay / ELISA. Enzyme-linked immunosorbent assay kits are fast, inexpensive, and widely used by ingredient suppliers for initial lot screening. They can return results within a few hours and detect aflatoxin at concentrations in the 1–5 ppb range. But ELISA methods have real limitations in botanical supplement matrices: they can cross-react with structurally similar compounds, they don’t distinguish between individual aflatoxin congeners (the difference between B1 and G1 matters when applying USP <561>‘s congener-specific limit), and high-pigment or high-fat matrices common in botanical extracts can suppress signal or produce false positives. ELISA is useful for supplier-level screening. It’s not adequate for finished product release or COA generation.

HPLC with fluorescence detection (HPLC-FLD). A validated, well-established approach for individual aflatoxin quantification. AOAC Method 2008.02 and AOAC 994.08 cover aflatoxins and OTA respectively using HPLC-FLD. It differentiates the four aflatoxin congeners and is more selective than immunoassay. The limitation is throughput: a run typically quantifies one mycotoxin group at a time, and complex botanical matrices often require more extensive cleanup before injection.

LC-MS/MS (liquid chromatography tandem mass spectrometry). The current standard for comprehensive mycotoxin panels. A single LC-MS/MS run can screen for aflatoxins B1, B2, G1, and G2; ochratoxin A; fumonisins B1 and B2; deoxynivalenol; zearalenone; and T-2 and HT-2 toxins simultaneously — typically at detection limits below 0.1 µg/kg. For any testing that needs to stand up to FDA scrutiny, support a Prop 65 defense, or serve as your quality record, LC-MS/MS is the only method worth specifying. ISO 17025 accreditation for the method is important here — it means measurement traceability and uncertainty have been formally validated, which matters if a result is ever challenged.

The practical protocol: use ELISA at the supplier level for rapid lot screening if you need a preliminary go/no-go before investing in full analytical testing. Use LC-MS/MS for any high-risk botanical ingredient with meaningful finished product volume, and for any incoming lot from a new supplier or new geographic origin.

What an Elevated Result Actually Requires You to Do

Most brands haven’t thought through the response protocol before they see a positive result. That’s when decisions get made poorly.

The most important thing to understand is that mycotoxins cannot be removed through downstream processing. Heat doesn’t destroy them — aflatoxins are stable at temperatures well above those used in standard manufacturing. You cannot wash, filter, or reformulate your way past contaminated starting material. Processing steps common in supplement manufacturing — blending, granulation, encapsulation, coating — have no effect on mycotoxin concentration.

The decision point is incoming raw material acceptance. Your supplier COA request should explicitly include mycotoxin testing, by an ISO 17025 accredited laboratory using LC-MS/MS. Lateral flow strips and in-house ELISA screening from a supplier’s quality department are not adequate documentation for a GMP quality system, and they wouldn’t hold up under audit.

When a lot comes back elevated, the path is clear: reject the material, quarantine it under your quality system, and issue a formal rejection notice to the supplier. There are no compliant remediation options for botanical supplement raw materials with confirmed mycotoxin contamination above specification limits. Document the out-of-specification event thoroughly. If the contaminated material entered a shared manufacturing environment, assess whether cross-contamination of other stored lots is possible.

We see meaningful variability in mycotoxin results across botanical lots sourced through common international supply channels — results on the same ingredient can vary by an order of magnitude between supplier batches, growing seasons, and origins. That variability is the whole argument for testing every incoming lot of high-risk botanicals, not sampling once a year and hoping the numbers stay stable.

If you’re building a mycotoxin testing protocol from scratch, start here: aflatoxin B1, B2, G1, and G2 plus ochratoxin A as your minimum panel, run against every new lot of high-risk botanical raw materials, with USP <561> limits written into your raw material specifications as the acceptance criteria. Add fumonisins and zearalenone if your formulas use corn-derived ingredients. Put the protocol in your specification documents so your contract manufacturer has a written acceptance threshold — not a verbal understanding.

The brands that get into trouble are almost always the ones who treated mycotoxin testing as something to do eventually.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• Raw Material COA Verification and Supplier Qualification — Ayah Labs covers USP/Ph.Eur. monograph-based testing for botanical raw materials and supplier qualification programs used by global ingredient buyers.
• FDA GMP Audit Preparation for Supplement Manufacturers — Aurora TIC guides dietary supplement brands through FDA 21 CFR Part 111 audit readiness, including documentation requirements for mycotoxin and contaminant controls.